NTGN Neon Therapeutics Inc

Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief Executive Officer of Neon, will present at the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15, 2019 at 5:00 p.m. PT (8:00 p.m. ET).

A live webcast of the presentation will be available by visiting the Investors section of Neon Therapeutics’ website at ir.neontherapeutics.com. A replay of the webcast will be archived on the Neon Therapeutics website for 30 days following the presentation.

About Neon Therapeutics

Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Neon is using its neoantigen platform to develop both vaccine and T cell therapies, including NEO-PV-01, a clinical stage neoantigen vaccine for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of a subset of hormone receptor-positive breast cancer.

For more information, please visit www.neontherapeutics.com.

Investor Contact:Paul Cox, Corporate Affairs and Strategypcox@neontherapeutics.com617-337-4762

Media Contact:Stephanie Simon, Ten Bridge Communicationsstephanie@tenbridgecommunications.com 617-581-9333